Company intelligence / Profile preview

Precigen

Germantown, Maryland, United Statesprecigen.com ↗

Ownership: Public · PGEN
Employees: ~600
Development stage: Phase 3

Overview

Precigen has demonstrated early clinical activity in several programs. For example, its PRGN‑3006 UltraCAR-T for AML/MDS received orphan drug status from the FDA. The company’s pipeline includes multiple gene and cell therapy candidates targeting both hematologic malignancies and solid tumors as well as autoimmune and infectious diseases. Several programs are in Phase 1/2 clinical trials with promising initial safety and efficacy data reported for some candidates

Therapeutic areas: GastroenterologyOncologyImmunologyInfectious Diseases
Modalities: Gene therapiescell therapies (including CAR-T)immunotherapies
Industry: Biotech

Drug pipeline

16 assets

zopapogene imadenovec

Approved

15 more assets in the full pipeline.

Request access →

Partnerships

Not specifically listed in search results; historically partnered with various biotech firms under Intrexon.

Financials

Market cap: $2.4B
Total revenue: $55M
Enterprise value: $2.4B

Beyond the preview

Go deeper on Precigen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Precigen.

Explore the full profile